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Copyright © 2009 JCBN Summary Astaxanthin (Ax), a carotenoid ubiquitously distributed in microorganisms, fish,
and crustaceans, has been known to be a potent antioxidant and hence exhibit various
physiological effects. We attempted in these studies to evaluate clinical toxicity and efficacy of
long-term administration of a new Ax product, by measuring biochemical and hematological
blood parameters and by analyzing brain function (using CogHealth and P300 measures).
Ax-rich  Haematococcus pluvialis extracts equivalent to 4, 8, 20 mg of Ax dialcohol were
administered to 73, 38, and 16 healthy adult volunteers, respectively, once daily for 4 weeks to
evaluate safety. Ten subjects with age-related forgetfulness received an extract equivalent to
12 mg in a daily dosing regimen for 12 weeks to evaluate efficacy. As a result, no abnormality
was observed and efficacy for age-related decline in cognitive and psychomotor functions was
suggested.
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Introduction
Astaxanthin (Ax) is a fat-soluble compound classified into
xanthophylls that are oxygenated derivatives of carotenoids.
In nature, Ax is a naturally-occurring red pigment and is
widely found in microorganisms (e.g., bacteria, microalgae,
yeast), crustaceans (e.g., lobster, krill, shrimp), fish (e.g.,
salmon, trout) and some birds (e.g., flamingo, quail) [1–4].
Despite the ubiquitous distribution of Ax, animals cannot
synthesize the carotenoid de novo, while microorganisms
and plants are able to produce it. Ax, particularly the
chemically-synthesized version, has therefore been used in
feed additives as a color enhancer in aquaculture and
chicken egg farms. Recently, attention has been focused on
the possible use of Ax in human health management,
because of its unique structural and chemical properties,
including strong antioxidant activity [1–8]. For this market,
a green microalga Haematococcus pluvialis, a red yeast
Phaffia rhodozyma and crustacean byproducts are commer-
cially available as natural sources of the pigment. Of these
three sources, H. pluvialis is known to be the richest source
of natural Ax (1.5–3.0% of the dry biomass) and various
algal cultivation systems (mainly outdoor systems) have
been developed at an industrial scale [2, 4, 5, 9–11]. As
pointed out by Margalith [12], light intensity and tempera-
ture are the most critical factors affecting both algal growth
and Ax accumulation. He also noted that a selective cultureToxicity and Efficacy of an Astaxanthin-Rich Algal Extract
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environment to prevent bacterial and/or protozoal over-
growth is a key factor to successful algal cultivation, but no
such environment is currently available for this alga. A
culturing technology which enables both higher Ax produc-
tion and greater sanitary control is therefore desired.
We have recently developed an indoor cultivation system,
namely the “YAMAHA High-efficiency Photobioreactor” to
manufacture Ax-containing H. pluvialis algal biomass. The
YAMAHA bioreactor is a vertical flat-plate type reactor
known to have excellent light illumination efficiency,
leading to superior algal growth [13]. The bioreactors are
illuminated continuously with strong synthetic light and
maintained at a desired temperature to maximize Ax
accumulation in algal cells. In order to minimize the risk of
contamination, the reactors are isolated in a Class 10,000
cleanroom; cultivation and all operations are performed in
this environment. High-quality and high-quantity Ax-
containing algal oil has thus been produced using these
bioreactors since October 2006, and the manufacturing
process was given GMP certification by the Japanese
Institute for Health Food Standards (JIHFS) in July 2007.
In the present study, we investigated the clinical safety of
this new Ax-rich oil, since it is qualitatively and quantita-
tively different from other existing Ax-containing H. pluvialis
oil products. Possible efficacy in the treatment of age-related
forgetfulness was also studied.
Methods
Clinical study design
All study protocols and informed consent documents
were reviewed and approved by the ethics committee of
the Yamaha Motor Co., Ltd. and Anti-Aging Science. All
study subjects provided written informed consent prior to
the start of study participation. The protocols were carried
out under the provisions of the Declaration of Helsinki.
Study 1
An open-label clinical study was conducted in 127
subjects between 20 to 60 years of age. The subjects were
divided into three groups, low-dose (Group A: 51 men, 22
women), middle-dose (Group B: 21 men, 17 women), and
high-dose (Group C: 12 men, 4 women). The subjects
ingested Ax-rich H. pluvialis oil (Puresta®, Yamaha Motor
Co., Ltd.; Iwata, Shizuoka, Japan) equivalent to 4 mg
(Group A), 8 mg (Group B), or 20 mg (Group C) of Ax
dialcohol contained in soft capsules, once daily for 4 weeks.
Blood biochemical and hematological examinations were
completed before (baseline) and after 4 weeks of dosing.
Differences between baseline and post-dosing values were
tested using Wilcoxon’s Signed Rank test (using SPSS for
Windows; SAS Institute, Cary, NC), where p<0.1 was
considered statistically significant.
Study 2
An open-label clinical study was conducted using 10
otherwise healthy male subjects (50–69 years of age) who
complained of age-related forgetfulness. The subjects
ingested Ax-rich H. pluvialis oil (Puresta®, Yamaha Motor
Co., Ltd.) equivalent to 12 mg of Ax dialcohol contained in
soft capsules once daily for 12 weeks. Cognitive function
was evaluated before administration (at baseline) and again
every 6 weeks during the study, using either the CogHealth
tool (CogState; Melbourne, Australia) or the event-related
P300 recognition response elicited by an auditory task [14].
Differences between baseline and post-baseline values were
analyzed using Dunnett’s multiple comparison test, where
p<0.05 was considered statistically significant and p<0.1
was considered as tendency toward significance.
Results
Study 1
The results of the blood pressure and hematological
examinations are shown in Table 1. Findings from the blood
biochemical examinations are shown in Table 2. Among
vital signs and laboratory analysis (hematology, hepatic, and
renal function tests) changes from baseline, no statistically
significant changes were noted for any of the dose groups.
There were no adverse effects or laboratory abnormalities
observed for any dose group. In addition, no adverse event
attributed to the administration of the test material was
reported in the subject interviews expect for ‘red stool’,
which was associated with the color of the test material.
We then attempted to predict clinical efficacy of Ax in the
treatment of metabolic syndrome. Subjects whose starting
systolic blood pressure (SBP), diastolic blood pressure
(DBP), triglyceride (TG) and fasting glucose (FG) values
meet the diagnosis of metabolic syndrome (SBP≥130
mmHg, DBP≥85 mmHg, TG≥150 mg/dl, and FG≥100 mg/dl;
[15]) were selected from Group A. Mean baseline values
were calculated and compared to those after treatment
(Fig. 1). As shown in Fig. 1A, a significant (p<0.01)
decrease in SBP was observed when subjects were admin-
istered 4 mg Ax orally once daily for 4 weeks. No such
decrease was apparent in DBP (Fig. 1B). The mean TG
value after treatment (218 mg/dl) was much lower than the
baseline value (292 mg/dl), although there was no statistical
significance between them (Fig. 1C). Fasting glucose
decreased with a tendency toward significance (p<0.1) after
treatment (Fig. 1D).
Study 2
In the present study, we investigated the effect of Ax on
brain function in healthy older adults with age-related
forgetfulness using the CogHealth test, since CogHealth is a
cognitive function test specifically designed to detect changesA. Satoh et al.
J. Clin. Biochem. Nutr.
282
in healthy or mildly-impaired subjects at an early date [16].
The test evaluates five cognitive domains—psychomotor
speed, impulse control, working memory, episodic learning,
and attention—by measuring the subject’s response times
(RTs) and accuracy (i.e., the hit rate percentage). Table 3
represents mean response time on the following CogHealth
tasks—simple reaction, choice reaction, working memory,
delayed recall, and divided attention—at baseline, and after
6 and 12 weeks of Ax treatment. The mean accuracy of the
‘working memory’ and ‘delayed recall’ tasks is also shown
in the table. Significant reduction in response time was
apparent for the ‘divided attention’ task after 6 weeks and on
all tasks after 12 weeks. The accuracy on the ‘working
memory’ task was improved significantly after 12 weeks of
treatment, while no such effect was observed for the
‘delayed recall’ task.
We then evaluated cognitive function using an event-
related potential, the P300, which reflects processes
involved in memory, response modulation, and contextual
updating, and has been used to evaluate mental workload
[17, 18]. The mean P300 latency and amplitude values at
baseline and after 12 weeks of treatment are shown in
Table 4. The P300 peak amplitude tended to increase (p<0.1)
after 12 weeks, while no such change was apparent in the
latency. It is thought that the amplitude and latency reflect
capacity and speed, respectively, of cognitive information
processing [19], and that both parameters closely relate to
selective attention [20]. The improving effect of Ax on the
amplitude of P300 therefore indicates that this carotenoid
might increase patient information processing capacity and
selective attention.
Table 1. Changes in blood pressure and hematological para-
meters (mean ± SD) before and after administration of
Puresta®
Group A = Puresta dose equivalent to 4 mg Ax/day, Group
B = Puresta dose equivalent to 8 mg Ax/day, Group C = Puresta
dose equivalent to 20 mg Ax/day.
No significant differences noted from baseline to end of treatment
for any of the treatment groups.
Parameter Group A Group B Group C
HBP (mm Hg)
before 121 ± 14 118 ± 14 119 ± 17
after 125 ± 12 122 ± 15 116 ± 13
LBP (mm Hg)
before 76 ± 12 74 ± 12 72 ± 14
after 78 ± 12 74 ± 13 68 ± 11
WBC (×109/liter)
before 5.7 ± 1.7 6.2 ± 1.6 5.5 ± 1.6
after 6.2 ± 2.1 6.0 ± 1.7 5.3 ± 0.8
RBC (×1012/liter)
before 4.7 ± 0.4 4.8 ± 0.6 4.8 ± 0.4
after 4.8 ± 0.6 4.9 ± 0.5 4.9 ± 0.5
Hb (g/liter)
before 144 ± 15 137 ± 21 148 ± 12
after 146 ± 15 139 ± 21 150 ± 13
Hct (%)
before 45 ± 44 3 ± 54 5 ± 3
after 46 ± 44 4 ± 54 6 ± 3
MCV (fL)
before 94 ± 69 0 ± 79 5 ± 4
after 95 ± 69 1 ± 79 5 ± 4
MCH (pg)
before 30.5 ± 2.4 28.9 ± 3.2 30.7 ± 1.6
after 30.2 ± 2.4 28.7 ± 3.3 30.6 ± 1.7
MCHC (%)
before 32 ± 13 2 ± 23 3 ± 1
after 32 ± 13 2 ± 23 2 ± 1
Platelets (×109/liter)
before 258 ± 50 279 ± 59 237 ± 52
after 256 ± 51 280 ± 58 239 ± 56
Table 2. Changes in blood biochemical parameters
(mean ± SD) before and after administration of Pur-
esta®
Group A = Puresta dose equivalent to 4 mg Ax/day.
Group B = Puresta dose equivalent to 8 mg Ax/day.
Group C = Puresta dose equivalent to 20 mg Ax/day.
No significant differences noted from baseline to end of treatment
for any of the treatment groups.
Parameter Group A Group B Group C
BUN (mg/dl)
before 12.7 ± 3.1 12.2 ± 2.5 12.1 ± 1.3
after 13.3 ± 3.1 12.6 ± 2.7 12.6 ± 1.7
Creatinine (mg/dl)
before 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.1
after 0.9 ± 0.1 0.9 ± 0.2 0.9 ± 0.1
Fasting glucose (mg/dl)
before 92 ± 13 95 ± 19 85 ± 12
after 93 ± 99 5 ± 15 91 ± 9
AST (U/liter)
before 23 ± 82 2 ± 52 4 ± 8
after 22 ± 82 2 ± 72 2 ± 8
ALT (U/liter)
before 25 ± 14 24 ± 13 32 ± 17
after 25 ± 13 23 ± 12 31 ± 21
γ-GTP (U/liter)
before 43 ± 33 34 ± 26 37 ± 23
after 46 ± 38 33 ± 22 33 ± 20Toxicity and Efficacy of an Astaxanthin-Rich Algal Extract
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Discussion
In the present study, we found that no abnormality was
apparent when adult subjects ingested Ax-containing H.
pluvialis oil product, Puresta®, up to 20 mg (equivalent to
Ax dialcohol) once daily for 4 weeks. The safety of Puresta®
has been investigated previously in a clinical study where 17
subjects were administered Puresta® amounts equivalent to
8 mg of Ax dialcohol twice daily for 12 weeks [21]. Our
current findings further support the safety of this product at
a dose of 20 mg/day, with no negative effects on blood
chemistry or hematology results over time, and no subject
reports of adverse experiences during treatment. We also
found positive effects of this product on metabolic syndrome
and cognitive function.
Metabolic syndrome is a common growing problem in
human health in industrialized countries. Hussen reported
that administration of astaxanthin decreased the blood
pressure of the SHR rat (a hypertensive rat model) [22].
However our study is the first instance to show efficacy in
humans. We observed previously that HbA1c and TNF-α
levels decreased significantly, while adiponectin levels
increased significantly when volunteers with borderline
metabolic syndrome were administered Puresta® equivalent
to 8 mg of Ax dialcohol twice daily for 12 weeks [21]. The
decreases in systolic blood pressure, triglyceride, and fasting
Fig. 1. Changes in systolic blood pressure (A), diastolic blood
pressure (B), triglyceride (C), and fasting glucose (D)
values before and after oral administration of Puresta
equivalent to 4 mg of Ax dialcohol once daily for 4
weeks. The number of subjects per group was 20, 16, 12,
and 10 in Groups A, B, C, and D, respectively. Error
bars represents standard deviations. *** and * represent
p<0.01 and p<0.1, respectively.
Table 3. Mean response times and accuracies (±SD) on CogHealth tasks at baseline, and after 6 and 12 weeks of Ax treatment.
** p<0.05 vs baseline.
Tasks
Mean ± SD
Baseline 6 weeks 12 weeks
Response time (ms)
Simple Reaction 341.68 ± 94.41 303.31 ± 33.80 281.76 ± 33.56**
Choice Reaction 504.53 ± 56.84 480.63 ± 39.87 463.63 ± 26.49**
Divided Attention 494.13 ± 135.57 419.52 ± 59.32** 412.07 ± 51.97**
Working Memory 762.94 ± 141.65 732.95 ± 174.83 654.83 ± 128.42**
Delayed Recall 1008.19 ± 153.37 975.40 ± 190.75 916.77 ± 151.04**
Accuracy (%)
Working Memory 90.46 ± 7.18 95.22 ± 5.37 96.30 ± 3.94**
Delayed Recall 70.95 ± 6.42 71.19 ± 5.98 70.71 ± 8.91
Table 4. Mean ( ± SD) P300 latency and amplitude values at
baseline and after 12 weeks of Ax treatment.




Latency (ms) 359.40 ± 16.49 363.10 ± 29.22
Amplitude (μV) 7.60 ± 4.05 10.54 ± 3.39*A. Satoh et al.
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glucose values observed in the present study may support
that the product has a beneficial effect in patients with
borderline diabetes mellitus or persons at risk for metabolic
syndrome.
The findings from our second study using CogHealth and
P300 suggest that administration of Ax might improve
higher brain function including cognition, attention, memory,
information processing, and resultant behaviors in older
persons. Little information is available in animal models in
regards to improvements in brain function with this food
supplement. Hussein et al. [22] reported that Ax showed
some memory-improving effects in ischemic mice. Admin-
istration of H. pluvialis powder also significantly improved
memory function in wild-type mice [23]. However, there
had been no study investigating effect on Ax on higher
cognitive function of human brain. To our knowledge, the
present study is the first report suggesting the beneficial
effects of Ax on cognitive function in humans. All tasks
investigated by CogHealth and P300 are indispensable for
skillful performance in the daily life activities. For example,
driving is a complex form of activity involving especially
cognitive and psychomotor functions. Age-related decreases
in these tasks are therefore a serious problem causing
increased number of death of old persons by traffic accident.
Ax would be a one of the promising food factors that
contribute to ameliorate those social problems. Further
clinical studies remain to be carried out to confirm these
possibilities.
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